JABIL INC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that JABIL INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Aug 31, 2019 | $25.28B | Oct 22, 2019 |
| FY2019 | Aug 31, 2018 | $22.10B | Oct 22, 2019 |
| FY2019 | Aug 31, 2017 | $19.06B | Oct 22, 2019 |
| FY2018 | Aug 31, 2016 | $18.35B | Oct 19, 2018 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | $29.80B | Oct 17, 2025 |
| FY2025 | Aug 31, 2024 | $28.88B | Oct 17, 2025 |
| FY2025 | Aug 31, 2023 | $34.70B | Oct 17, 2025 |
| FY2024 | Aug 31, 2022 | $33.48B | Oct 28, 2024 |
| FY2023 | Aug 31, 2021 | $29.29B | Oct 20, 2023 |
| FY2022 | Aug 31, 2020 | $27.27B | Oct 25, 2022 |
| FY2021 | Aug 31, 2019 | $25.28B | Oct 22, 2021 |
| FY2020 | Aug 31, 2018 | $22.10B | Oct 22, 2020 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Aug 31, 2017 | $19.06B | Oct 19, 2017 |
| FY2017 | Aug 31, 2016 | $18.35B | Oct 19, 2017 |
| FY2017 | Aug 31, 2015 | $17.90B | Oct 19, 2017 |
| FY2016 | Aug 31, 2014 | $15.76B | Oct 20, 2016 |
| FY2015 | Aug 31, 2013 | $17.25B | Oct 16, 2015 |
| FY2014 | Aug 31, 2012 | $16.14B | Oct 21, 2014 |
| FY2013 | Aug 31, 2011 | $16.52B | Oct 28, 2013 |
| FY2012 | Aug 31, 2010 | $13.41B | Oct 25, 2012 |
| FY2011 | Aug 31, 2009 | $11.68B | Oct 27, 2011 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | $2.65B | Oct 17, 2025 |
| FY2025 | Aug 31, 2024 | $2.68B | Oct 17, 2025 |
| FY2025 | Aug 31, 2023 | $2.87B | Oct 17, 2025 |
| FY2024 | Aug 31, 2022 | $2.63B | Oct 28, 2024 |
| FY2023 | Aug 31, 2021 | $2.36B | Oct 20, 2023 |
| FY2022 | Aug 31, 2020 | $1.93B | Oct 25, 2022 |
| FY2021 | Aug 31, 2019 | $1.91B | Oct 22, 2021 |
| FY2020 | Aug 31, 2018 | $1.71B | Oct 22, 2020 |
| FY2019 | Aug 31, 2017 | $1.55B | Oct 22, 2019 |
| FY2018 | Aug 31, 2016 | $1.53B | Oct 19, 2018 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | $657.00M | Oct 17, 2025 |
| FY2025 | Aug 31, 2024 | $1.39B | Oct 17, 2025 |
| FY2025 | Aug 31, 2023 | $818.00M | Oct 17, 2025 |
| FY2024 | Aug 31, 2022 | $996.00M | Oct 28, 2024 |
| FY2023 | Aug 31, 2021 | $696.00M | Oct 20, 2023 |
| FY2022 | Aug 31, 2020 | $54.00M | Oct 25, 2022 |
| FY2021 | Aug 31, 2019 | $287.00M | Oct 22, 2021 |
| FY2020 | Aug 31, 2018 | $86.33M | Oct 22, 2020 |
| FY2019 | Aug 31, 2017 | $129.09M | Oct 22, 2019 |
| FY2018 | Aug 31, 2016 | $254.10M | Oct 19, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | $1.18B | Oct 17, 2025 |
| FY2025 | Aug 31, 2024 | $2.01B | Oct 17, 2025 |
| FY2025 | Aug 31, 2023 | $1.54B | Oct 17, 2025 |
| FY2024 | Aug 31, 2022 | $1.39B | Oct 28, 2024 |
| FY2023 | Aug 31, 2021 | $1.06B | Oct 20, 2023 |
| FY2022 | Aug 31, 2020 | $500.00M | Oct 25, 2022 |
| FY2021 | Aug 31, 2019 | $701.00M | Oct 22, 2021 |
| FY2020 | Aug 31, 2018 | $542.15M | Oct 22, 2020 |
| FY2019 | Aug 31, 2017 | $410.23M | Oct 22, 2019 |
| FY2018 | Aug 31, 2016 | $522.83M | Oct 19, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | $26.00M | Oct 17, 2025 |
| FY2025 | Aug 31, 2024 | $39.00M | Oct 17, 2025 |
| FY2025 | Aug 31, 2023 | $34.00M | Oct 17, 2025 |
| FY2024 | Aug 31, 2022 | $33.00M | Oct 28, 2024 |
| FY2023 | Aug 31, 2021 | $34.00M | Oct 20, 2023 |
| FY2022 | Aug 31, 2020 | $43.00M | Oct 25, 2022 |
| FY2021 | Aug 31, 2019 | $43.00M | Oct 22, 2021 |
| FY2020 | Aug 31, 2018 | $38.53M | Oct 22, 2020 |
| FY2019 | Aug 31, 2017 | $29.68M | Oct 22, 2019 |
| FY2018 | Aug 31, 2016 | $31.95M | Oct 19, 2018 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | $1.12B | Oct 17, 2025 |
| FY2025 | Aug 31, 2024 | $1.16B | Oct 17, 2025 |
| FY2025 | Aug 31, 2023 | $1.21B | Oct 17, 2025 |
| FY2024 | Aug 31, 2022 | $1.15B | Oct 28, 2024 |
| FY2023 | Aug 31, 2021 | $1.21B | Oct 20, 2023 |
| FY2022 | Aug 31, 2020 | $1.18B | Oct 25, 2022 |
| FY2021 | Aug 31, 2019 | $1.11B | Oct 22, 2021 |
| FY2020 | Aug 31, 2018 | $1.05B | Oct 22, 2020 |
| FY2019 | Aug 31, 2017 | $907.70M | Oct 22, 2019 |
| FY2018 | Aug 31, 2016 | $924.43M | Oct 19, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | $1.64B | Oct 17, 2025 |
| FY2025 | Aug 31, 2024 | $1.72B | Oct 17, 2025 |
| FY2025 | Aug 31, 2023 | $1.73B | Oct 17, 2025 |
| FY2024 | Aug 31, 2022 | $1.65B | Oct 28, 2024 |
| FY2023 | Aug 31, 2021 | $1.43B | Oct 20, 2023 |
| FY2022 | Aug 31, 2020 | $1.26B | Oct 25, 2022 |
| FY2021 | Aug 31, 2019 | $1.19B | Oct 22, 2021 |
| FY2020 | Aug 31, 2018 | ($1.11B) | Oct 22, 2020 |
| FY2019 | Aug 31, 2017 | ($1.46B) | Oct 22, 2019 |
| FY2018 | Aug 31, 2016 | $916.21M | Oct 19, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | $468.00M | Oct 17, 2025 |
| FY2025 | Aug 31, 2024 | $784.00M | Oct 17, 2025 |
| FY2025 | Aug 31, 2023 | $1.03B | Oct 17, 2025 |
| FY2024 | Aug 31, 2022 | $1.39B | Oct 28, 2024 |
| FY2023 | Aug 31, 2021 | $1.16B | Oct 20, 2023 |
| FY2022 | Aug 31, 2020 | $983.00M | Oct 25, 2022 |
| FY2021 | Aug 31, 2019 | $1.01B | Oct 22, 2021 |
| FY2020 | Aug 31, 2018 | $1.04B | Oct 22, 2020 |
| FY2019 | Aug 31, 2017 | $716.49M | Oct 22, 2019 |
| FY2018 | Aug 31, 2016 | $924.24M | Oct 19, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | $18.54B | Oct 17, 2025 |
| FY2025 | Aug 31, 2024 | $17.35B | Oct 17, 2025 |
| FY2024 | Aug 31, 2023 | $19.42B | Oct 28, 2024 |
| FY2023 | Aug 31, 2022 | $19.72B | Oct 20, 2023 |
| FY2022 | Aug 31, 2021 | $16.65B | Oct 25, 2022 |
| FY2021 | Aug 31, 2020 | $14.40B | Oct 22, 2021 |
| FY2020 | Aug 31, 2019 | $12.97B | Oct 22, 2020 |
| FY2019 | Aug 31, 2018 | $12.05B | Oct 22, 2019 |
| FY2018 | Aug 31, 2017 | $11.10B | Oct 19, 2018 |
| FY2017 | Aug 31, 2016 | $10.32B | Oct 19, 2017 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | $17.03B | Oct 17, 2025 |
| FY2025 | Aug 31, 2024 | $15.61B | Oct 17, 2025 |
| FY2024 | Aug 31, 2023 | $16.56B | Oct 28, 2024 |
| FY2023 | Aug 31, 2022 | $17.27B | Oct 20, 2023 |
| FY2022 | Aug 31, 2021 | $14.52B | Oct 25, 2022 |
| FY2021 | Aug 31, 2020 | $12.57B | Oct 22, 2021 |
| FY2020 | Aug 31, 2019 | $11.07B | Oct 22, 2020 |
| FY2019 | Aug 31, 2018 | $10.08B | Oct 22, 2019 |
| FY2018 | Aug 31, 2017 | $8.73B | Oct 19, 2018 |
| FY2017 | Aug 31, 2016 | $7.87B | Oct 19, 2017 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | $1.51B | Oct 17, 2025 |
| FY2025 | Aug 31, 2024 | $1.74B | Oct 17, 2025 |
| FY2024 | Aug 31, 2023 | $2.87B | Oct 28, 2024 |
| FY2023 | Aug 31, 2022 | $2.45B | Oct 20, 2023 |
| FY2022 | Aug 31, 2021 | $2.14B | Oct 25, 2022 |
| FY2021 | Aug 31, 2020 | $1.81B | Oct 22, 2021 |
| FY2020 | Aug 31, 2019 | $1.89B | Oct 22, 2020 |
| FY2019 | Aug 31, 2018 | $1.95B | Oct 22, 2019 |
| FY2018 | Aug 31, 2017 | $2.35B | Oct 19, 2018 |
| FY2017 | Aug 31, 2016 | $2.44B | Oct 19, 2017 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | $841.00M | Oct 17, 2025 |
| FY2025 | Aug 31, 2024 | $661.00M | Oct 17, 2025 |
| FY2025 | Aug 31, 2023 | $621.00M | Oct 17, 2025 |
| FY2024 | Aug 31, 2022 | $704.00M | Oct 28, 2024 |
| FY2023 | Aug 31, 2021 | $715.00M | Oct 20, 2023 |
| FY2022 | Aug 31, 2020 | $697.00M | Oct 25, 2022 |
| FY2021 | Aug 31, 2019 | $622.00M | Oct 22, 2021 |
| FY2020 | Aug 31, 2018 | $627.75M | Oct 22, 2020 |
| FY2019 | Aug 31, 2017 | $608.18M | Oct 22, 2019 |
| FY2018 | Aug 31, 2016 | $594.77M | Oct 19, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | $6.38B | Oct 17, 2025 |
| FY2025 | Aug 31, 2024 | $5.76B | Oct 17, 2025 |
| FY2024 | Aug 31, 2023 | $4.41B | Oct 28, 2024 |
| FY2023 | Aug 31, 2022 | $3.64B | Oct 20, 2023 |
| FY2022 | Aug 31, 2021 | $2.69B | Oct 25, 2022 |
| FY2021 | Aug 31, 2020 | $2.04B | Oct 22, 2021 |
| FY2020 | Aug 31, 2019 | $2.04B | Oct 22, 2020 |
| FY2019 | Sep 1, 2018 | $1.80B | Oct 22, 2019 |
| FY2019 | Aug 31, 2018 | $1.76B | Oct 22, 2019 |
| FY2018 | Aug 31, 2017 | $1.73B | Oct 19, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | $1.93B | Oct 17, 2025 |
| FY2025 | Aug 31, 2024 | $2.20B | Oct 17, 2025 |
| FY2024 | Aug 31, 2023 | $1.80B | Oct 28, 2024 |
| FY2023 | Aug 31, 2022 | $1.48B | Oct 20, 2023 |
| FY2022 | Aug 31, 2021 | $1.57B | Oct 25, 2022 |
| FY2021 | Aug 31, 2020 | $1.39B | Oct 22, 2021 |
| FY2020 | Aug 31, 2019 | $1.16B | Oct 22, 2020 |
| FY2019 | Aug 31, 2018 | $1.26B | Oct 22, 2019 |
| FY2019 | Aug 31, 2017 | $1.19B | Oct 22, 2019 |
| FY2019 | Aug 31, 2016 | $912.06M | Oct 22, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | $2.89B | Oct 17, 2025 |
| FY2025 | Aug 31, 2024 | $2.88B | Oct 17, 2025 |
| FY2024 | Aug 31, 2023 | $2.88B | Oct 28, 2024 |
| FY2023 | Aug 31, 2022 | $2.88B | Oct 20, 2023 |
| FY2022 | Aug 31, 2021 | $2.88B | Oct 25, 2022 |
| FY2021 | Aug 31, 2020 | $2.73B | Oct 22, 2021 |
| FY2020 | Aug 31, 2019 | $2.50B | Oct 22, 2020 |
| FY2019 | Aug 31, 2018 | $2.52B | Oct 22, 2019 |
| FY2018 | Aug 31, 2017 | $2.05B | Oct 19, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | 6 | Oct 17, 2025 |
| FY2025 | Aug 31, 2024 | 11 | Oct 17, 2025 |
| FY2025 | Aug 31, 2023 | 6 | Oct 17, 2025 |
| FY2024 | Aug 31, 2022 | 7 | Oct 28, 2024 |
| FY2023 | Aug 31, 2021 | 4 | Oct 20, 2023 |
| FY2022 | Aug 31, 2020 | 0 | Oct 25, 2022 |
| FY2021 | Aug 31, 2019 | 1 | Oct 22, 2021 |
| FY2020 | Aug 31, 2018 | 0 | Oct 22, 2020 |
| FY2019 | Aug 31, 2017 | 0 | Oct 22, 2019 |
| FY2018 | Aug 31, 2016 | 1 | Oct 19, 2018 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | 5 | Oct 17, 2025 |
| FY2025 | Aug 31, 2024 | 11 | Oct 17, 2025 |
| FY2025 | Aug 31, 2023 | 6 | Oct 17, 2025 |
| FY2024 | Aug 31, 2022 | 6 | Oct 28, 2024 |
| FY2023 | Aug 31, 2021 | 4 | Oct 20, 2023 |
| FY2022 | Aug 31, 2020 | 0 | Oct 25, 2022 |
| FY2021 | Aug 31, 2019 | 1 | Oct 22, 2021 |
| FY2020 | Aug 31, 2018 | 0 | Oct 22, 2020 |
| FY2019 | Aug 31, 2017 | 0 | Oct 22, 2019 |
| FY2018 | Aug 31, 2016 | 1 | Oct 19, 2018 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | 107.48M | Oct 17, 2025 |
| FY2025 | Aug 31, 2024 | 113.74M | Oct 17, 2025 |
| FY2024 | Aug 31, 2023 | 131.29M | Oct 28, 2024 |
| FY2023 | Aug 31, 2022 | 135.49M | Oct 20, 2023 |
| FY2022 | Aug 31, 2021 | 144.50M | Oct 25, 2022 |
| FY2021 | Aug 31, 2020 | 150.33M | Oct 22, 2021 |
| FY2020 | Aug 31, 2019 | 153.52M | Oct 22, 2020 |
| FY2019 | Aug 31, 2018 | 164.59M | Oct 22, 2019 |
| FY2018 | Aug 31, 2017 | 177.73M | Oct 19, 2018 |
| FY2016 | Aug 31, 2016 | 187.00M | Oct 20, 2016 |